[go: up one dir, main page]

WO2011149766A2 - Agents pharmaceutiques à lipides personnalisés - Google Patents

Agents pharmaceutiques à lipides personnalisés Download PDF

Info

Publication number
WO2011149766A2
WO2011149766A2 PCT/US2011/037270 US2011037270W WO2011149766A2 WO 2011149766 A2 WO2011149766 A2 WO 2011149766A2 US 2011037270 W US2011037270 W US 2011037270W WO 2011149766 A2 WO2011149766 A2 WO 2011149766A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
omega
therapeutic agent
fatty acid
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/037270
Other languages
English (en)
Other versions
WO2011149766A3 (fr
Inventor
Jingxuan Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011149766A2 publication Critical patent/WO2011149766A2/fr
Publication of WO2011149766A3 publication Critical patent/WO2011149766A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/06—Aluminium compounds
    • C07F5/069—Aluminium compounds without C-aluminium linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • niacin blocks breakdown of fats, it causes a decrease in free fatly acids in the blood and, as a consequence, decreased secretion of VLDL and cholesterol by the liver, ( aizung, Bertram G. (2006), Basic and clinical pharmacology, New York; McGraw-Hill Medical Publishing Division,)
  • Omega-3 fatty acids are also safe and natural compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne, d'une manière générale, de nouveaux agents thérapeutiques. Plus particulièrement, l'invention concerne de nouveaux composés ayant une fraction qui fournit les avantages des acides gras oméga-3 et une fraction qui fournit des avantages thérapeutiques utiles, tels que la diminution du cholestérol du sang, l'atténuation de l'inflammation, la réduction des triglycérides, l'augmentation des lipoprotéines à haute densité, etc. De tels agents thérapeutiques améliorent le métabolisme des médicaments et la pharmacocinétique, fournissent une meilleur efficacité et réduisent les effets secondaires.
PCT/US2011/037270 2010-05-23 2011-05-20 Agents pharmaceutiques à lipides personnalisés Ceased WO2011149766A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34744910P 2010-05-23 2010-05-23
US61/347,449 2010-05-23

Publications (2)

Publication Number Publication Date
WO2011149766A2 true WO2011149766A2 (fr) 2011-12-01
WO2011149766A3 WO2011149766A3 (fr) 2012-04-19

Family

ID=45004679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/037270 Ceased WO2011149766A2 (fr) 2010-05-23 2011-05-20 Agents pharmaceutiques à lipides personnalisés

Country Status (1)

Country Link
WO (1) WO2011149766A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685969A4 (fr) * 2011-03-18 2014-08-06 Catabasis Pharmaceuticals Inc Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
EP2844257A4 (fr) * 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Conjugués d'acide gras de statine et d'agonistes de fxr ; compositions et procédés d'utilisation
US10774059B2 (en) 2016-12-19 2020-09-15 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713045B2 (en) * 1995-05-01 1999-11-25 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them
CA2556520C (fr) * 2005-01-27 2008-10-28 Ocean Nutrition Canada Ltd. Composes a base de chrome et d'acide gras et methodes de production et d'utilisation connexes
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
WO2008053331A1 (fr) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Lipides oméga-3 à substitution alpha en tant qu'activateurs ou modulateurs du récepteur activé par proliférateurs de peroxisome (ppar)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685969A4 (fr) * 2011-03-18 2014-08-06 Catabasis Pharmaceuticals Inc Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
EP2844257A4 (fr) * 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Conjugués d'acide gras de statine et d'agonistes de fxr ; compositions et procédés d'utilisation
US10774059B2 (en) 2016-12-19 2020-09-15 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation

Also Published As

Publication number Publication date
WO2011149766A3 (fr) 2012-04-19

Similar Documents

Publication Publication Date Title
AU2020205213B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
RU2509071C2 (ru) Новые липидные соединения
JP4476479B2 (ja) 糖尿病合併症の治療または予防のための薬剤
US7807718B2 (en) Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US20150038469A1 (en) Compositions for treatment of cardiometabolic disorders
JP3103588B2 (ja) リポプロテイン（ａ）低下剤
SK14502003A3 (en) Coenzyme Q and eicosapentaenoic acid
US20140107206A1 (en) Omega-3 pentaenoic acid compositions and methods of use
KR102265409B1 (ko) 지질 화합물을 이용한 치료방법
JP5575651B2 (ja) 新規のｄｈａ誘導体およびその医薬品としての用途
WO2013136277A1 (fr) Compositions pharmaceutiques pour le traitement de maladies cardiovasculaires
JP5552314B2 (ja) 新規脂質化合物
JP2015508065A (ja) 抗炎症薬としての脂肪酸
US20100266681A1 (en) Fatty acid alcohols
JP2021035956A (ja) 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
JP2016518315A (ja) ω３ペンタエン酸組成物および使用方法
WO2011149766A2 (fr) Agents pharmaceutiques à lipides personnalisés
CN112107570A (zh) 施用包含二十二碳五烯酸的组合物的方法
RU2705991C2 (ru) Применение тиаоксосоединений для уменьшения содержания аро с3
KR20080033410A (ko) 페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
US20150374660A1 (en) Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses
KR20070108383A (ko) 지질 저하성 화합물
EP3116493A1 (fr) Compositions et procédés pour atténuer une inflammation chronique de faible intensité
TW546138B (en) Compounds with 1,3-propane diol linked structure and 1,3-propane diol derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11787155

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11787155

Country of ref document: EP

Kind code of ref document: A2